Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses

Genprex, Inc.

New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.
Acclaim-1 Phase 2a enrolling; Phase 1 showed no DLTs, one patient had partial remission for ~42 months (60 courses) on Reqorsa+Tagrisso.
Acclaim-3 Phase 2 enrolling; Phase 1 showed no DLTs, one patient had unconfirmed partial remission after 24 cycles (>18 months) on Reqorsa+Tecentriq.
Both trials combine Reqorsa (quaratusugene ozeplasmid) with approved targeted therapies; early signs of efficacy reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.